Cutaneous and noncutaneous disorders treated with extracorporeal photopheresis

International Journal of Dermatology

Volumn 40, Issue 2, 2001, Pages 89-100

  Russo, Glenn G ^a   Mullen, Cynthia ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIMALARIAL AGENT; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DNA; EOSINOPHIL CATIONIC PROTEIN; GAMMA INTERFERON; GLUCOCORTICOID; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENT; ISOTRETINOIN; METHOTREXATE; METHOXSALEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PREDNISONE; TACROLIMUS;

AIDS RELATED COMPLEX; ATOPIC DERMATITIS; B CELL LEUKEMIA; B CELL LYMPHOMA; CHILL; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DRUG MECHANISM; EPIDERMOLYSIS BULLOSA ACQUISITA; FEVER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEADACHE; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LEUKAPHERESIS; LICHEN PLANUS; MULTIPLE SCLEROSIS; MYXEDEMA; NONHUMAN; PEMPHIGOID; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; REVIEW; RHEUMATOID ARTHRITIS; SCLEREDEMA; SKIN DISEASE; T CELL LYMPHOMA; TREATMENT FAILURE; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; VIRUS INACTIVATION;

HUMANS; IMMUNE SYSTEM DISEASES; PHOTOPHERESIS; SKIN DISEASES; VIRUS DISEASES;

EID: 0035038188     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2001.01182.x     Document Type: Review

References (90)

1. Photopheresis and autoimmune diseases
2. The impact of psoralen photoadducts in cells
3. A method for the determination of PUVA-induced in vivo irreversible binding of 8-methoxypsoralen (8-MOP) to epidermal lipids, proteins, and DNA/RNA
4. Clinical and mechanistic aspects of photopheresis
5. DNA associated with the cell membrane is involved in the inhibition of the skin rejection response induced by infusion of photodamaged alloreactive cells that regulate rejection of skin allograft
6. Mechanism of photochemotherapy-induced apoptotic cell death in lymphoid cells
7. Extracorporeal photochemotherapy induces the production of tumor necrosis factor-alpha by monocytes: Implication for the treatment of cutaneous T-cell lymphoma and systemic sclerosis
8. Extracorporeal photochemotherapy induces a significant increase in CD36+ circulating monocytes in patients with mycosis fungoides
9. Extracorporeal photochemotherapy does not suppress T- or B-cell responses to novel or recall antigens
10. Adverse effects associated with extracorporeal photochemotherapy
11. Frequency of immediate adverse effects associated with therapeutic apheresis
12. Extracorporeal photopheresis
13. Inactivation of human T-cell virus type III: Heat, chemicals, and irradiation
14. Extracorporeal photopheresis in the acquired immunodeficiency syndrome (AIDS)-related complex: A pilot study
15. Extracorporeal photopheresis in the treatment of AIDS-related complex: Extended trial
16. Lesional expression of gamma-interferon in atopic ezcema
17. Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reaction of atopic dermatitis
18. Biphase response against aeroallergen in atopic dermatitis showing a switch from an initial Th 2 response to a Th 1 response in situ: An immunocytochemical study
19. Allergen specificity of skin infiltrating T cells is not restricted to a type-2 cytokine pattern in chronic skin lesions of atopic dermatitis
20. Successful monotherapy of severe and intractable atopic dermatitis by photopheresis
21. Treatment of severe atopic dermatitis with extracorporeal photopheresis
22. Quality of life improvement in a patient with severe atopic dermatitis treated with photopheresis
23. Phototherapy for atopic eczema with narrowband UVB
24. Combined UVA-UVB versus UVB phototherapy for atopic dermatitis: A comparison study
25. Medium dose UVA-1 cold light phototherapy in the treatment of severe atopic dermatitis
26. Tacrolimus (FK 506) ointment for atopic dermatitis: A phase I study in adults and children
27. Inefficacy of extracorporeal photochemotherapy in the treatment of B-cell chronic lymphocytic leukemia: Preliminary results
28. Short-time extracorporeal photochemotherapy in the treatment of drug-resistant autoimmune bullous diseases
29. Cellular immunity in polymyositis dermatomyositis
30. Mechanism of the damaging effect of dermatomyositis mononuclear cells on cultured human skin fibroblasts
31. Extracorporeal photochemotherapy as adjunctive treatment in juvenile dermatomyositis: A case report
32. Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus - A pilot study
33. Inhibition of autoimmune disease in a murine model of systemic lupus erythematosus induced by exposure to syngeneic photoactivated lymphocytes
34. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial
35. Extracorporeal photochemotherapy in systemic sclerosis and severe morphea
36. Management of severe scleroderma with long-term extracorporeal photopheresis
37. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis)
38. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy
39. Extracorporeal photochemotherapy induces apoptosis of infiltrating lymphoid cells in patients with mycosis fungoides in early stages. A quantitative histological study
40. 4+ T lymphocytes
41. Extracorporeal photochemotherapy
42. Photoactivated 8-methoxy-psoralen treatment causes a peptide-dependent increase in antigen displays by transformed lymphocytes
43. Extracorporeal photochemotherapy restores Th1/Th2 imbalance in patients with early stage cutaneous T-cell lymphoma
44. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline need for randomized studies
45. Photopheresis therapy of cutaneous T-cell lymphoma: The Yale-New Heaven Hospital experience
46. Extracorporeal photopheresis for the treatment of 34 patients with cutaneous T-cell lymphoma (CTCL)
47. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon-alpha: A 10 year experience at a single institution
48. 4+/CD8+ ratio and rapidity of response are predictors of outcome in treatment of CTCL with extracorporeal photochemotherapy (ECP)
49. Photopheresis therapy for cutaneous T-cell lymphoma
50. Long term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy
51. Extracorporeal photopheresis in Sézary syndrome
52. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma
53. Photopheresis in the red man or pre-Sézary syndrome
54. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: A 9.7 year experience
55. Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with peripheral blood T-cell clone
56. Effectiveness of photopheresis in Sézary syndrome
57. In reply
58. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: A 9-year retrospective study at a single institution
59. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy
60. Remission of severe epidermolysis by extracorporeal photochemotherapy
61. Successful treatment of chronic graft versus host disease with extracorporeal photopheresis
62. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft versus host disease patients
63. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host-disease
64. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD)
65. Extracorporeal photopheresis along with interferon-alpha 2a in chronic hepatitis C patients who failed previous interferon therapy
66. Extracorporeal photochemotherapy for chronic erosive lichen planus
67. Animal models
68. Specific vaccination against photoactivated cloned T cells
69. Photopheresis - A possible treatment of multiple sclerosis? Report of two cases
70. A double-blind placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis
71. Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris
72. Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresis
73. Extracorporeal photochemotherapy for Epstein-Barr virus-associated lymphoma after lung transplantation
74. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy
75. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: Ten years of cyclosporine-based immunosuppression
76. Extracorporeal photopheresis in psoriasis vulgaris: Clinical and immunologic observations
77. Treatment of psoriatic arthritis with extracorporeal photochemotherapy and conventional psoralen-ultraviolet A irradiation
78. Psoriatic arthritis: One year of treatment with extracorporeal photochemotherapy
79. Successful treatment of recurrent rejection in renal transplant patients with photpheresis
80. Photopheresis for renal allograft rejection
81. Reversal of acute renal allograft rejection by extracorporeal photopheresis
82. Benefits of photopheresis in the treatment of heart transplant patients with multiple refractory rejection
83. Efficacy of photopheresis in the rescue therapy of acute cellular rejection in human heart allografts: A preliminary clinical and immunopathologic report
84. Photopheresis for recurrent acute rejection in cardiac transplantation
85. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation
86. Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis
87. Treatment of rheumatoid arthritis by extracorporeal photopheresis: A pilot study
88. Scleredema associated with paraproteinemia treated by extracorporeal photopheresis
89. Remission of scleromyxedema following treatment with extracorporeal photopheresis
90. Extracorporeal photochemotherapy: A potentially useful treatment for scleromyxedema